Clinical OMICS

NOV-DEC 2017

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 44 of 47 November/December 2017 Clinical OMICs 43 Precision Medicine Forms Healthcare Value Units Precision Medicine Group has formed a new business focused on helping clients demonstrate the clinical, economic, and humanistic value of their therapies to pay- ers, healthcare professionals, and patients. Precision Value & Health offers services that include global pricing and market access support, health economics and out- comes research, managed markets market- ing, and promotional effectiveness through value message development and brand engagement. Clients are expected to include biopharmas and other life sciences companies. Precision Value & Health said it will draw upon more than 500 employees in 10 offices across North America and Europe, and combine the offerings of three business units. One of those units, Precision for Value, will leverage a team of payer executives who will specialize in ensuring maximum market access and reimbursement by insurers for medical innovations. The executives will develop distinctive payer value propositions and solutions for products that are designed to differentiate them from competitors, Precision Value & Health said. Another unit, Precision Health Economics, has been formed to influence pol- icy debates on critical healthcare issues by offering what it says will be innova- tive health policy research and economic analysis, along with evidence synthesis methods, models, strategies, and communications plans. A third unit, precisioneffect, is a healthcare advertising agency focused on work- ing with companies committed to redefining the standard of care among physi- cians, patients, and caregivers. The agency—which operates from headquarters in Boston and Costa Mesa, CA—is a finalist for three 2017 MM&M Awards honoring creativity and effectiveness in healthcare marketing and communications. "Precision Value & Health has a wide range of experts and services that help our customers stay ahead in an ever-changing healthcare landscape," Dan Renick, president of Precision Value & Health, said in a statement. "Our expertise is in recognizing change and delivering new customized solutions for a dynamic environment." Precision Value & Health is one of two entities of Precision Medicine Group. The other is Precision for Medicine, a precision medicine research company focused on biomarker-driven therapeutic development—in part through its expanding Precision Oncology CRO, which serves developers of targeted cancer treatments. Precision Medicine Group, established in 2012, is a specialized services com- pany created to support next-generation approaches to drug development and commercialization. The company is headquartered in Bethesda, MD, with offices throughout North America and Europe. Prescient Medicine Acquires PGxL Laboratories Predictive health intelligence company Prescient Medicine, has acquired PGxL Laboratories, a leading reference lab for pharmacogenetics testing. The acquisi- tion expands Prescient's laboratory capa- bilities, and allows it to strengthen its working relationships with health insur- ers, and potentially offering patients better access to their suite of pharma- cogenomic tools. Pharmacogenomic testing provides information on an individual's ability to process certain drugs based on their genetic makeup. One area of growth for Prescient is its validated genetic test, LifeKit Predict, that assesses an patient's genetic risk of opioid addiction. LifeKit Predict, along with the company's other genetic tests, will be processed at the Louisville facility by the end of the year. "In light of the current opioid crisis, it's important that, as a company, Prescient continuously finds opportunities to develop, enhance, and refine tools that can better predict and inform patient outcomes," said Keri Donaldson, M.D., founder and CEO of Prescient Medicine. "The purchase of PGxL is an opportu- nity to better service the growing list of clinics, doctors, and patients who see the value in important clinical tools like LifeKit Predict. We're excited about the potential to drive better access to our genetic tools for the patients who need them most." n Megan Miks / Getty Images solidcolours / Getty Images

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - NOV-DEC 2017